Post-Injury Delivery of rAAV2-CNTF Combined with Short-Term Pharmacotherapy Is Neuroprotective and Promotes Extensive Axonal Regeneration after Optic Nerve Trauma
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viral (rAAV) vectors expressing neurotrophic genes reduce neuronal death and promote axonal regeneration in central nervous system (CNS) injury models. Currently, however, use of rAAV to treat clinical neurotrauma is problematic because there is a delay in the onset of transgene expression. Using the adult rat retina and optic nerve (ON), we have tested whether rAAV gene therapy administered at the time of injury combined with short-term pharmacotherapy has synergistic effects that enhance neuronal survival and regeneration. The ON was transected and a 1.5 cm segment of autologous peripheral nerve (PN) was grafted onto the cut end. At this time, bicistronic rAAV2 encoding ciliary neurotrophic factor (CNTF) and green fluorescent protein (rAAV2-CNTF-GFP) was injected into the injured eye. To provide interim support for axotomized retinal ganglion cells (RGCs) during vector integration and therapeutic transgene expression, rCNTF protein and a cyclic adenosine monophosphate (cAMP) analogue (CPT-cAMP) were injected intravitreally 3 and 10 days postoperatively. For comparison, another rAAV2-CNTF-GFP group received two intravitreal saline injections 3 and 10 days after the PN-ON surgery. A further PN graft group received only postoperative intravitreal injections of rCNTF plus CPT-cAMP. After 4 weeks, regenerating RGCs were retrogradely labelled by applying fluorogold to the distal end of each PN graft. Compared to saline-injected animals, both RGC survival and axonal regrowth were significantly higher in the rCNTF and CPT-cAMP injected rAAV2-CNTF-GFP group; approximately one third of the RGC population survived axotomy, and 27% of these regrew an axon. These values were also higher than those obtained in rats that received only rCNTF plus CPT-cAMP injections. Therefore, we show for the first time that rAAV-mediated gene delivery at the time of, or just after, neurotrauma is most successful when combined with temporary post-injury trophic support, and is potentially a viable treatment strategy for patients after acute CNS injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“…has resulted in a gain of visual function in patients with the inherited blinding disease Leber’s congenital amaurosis (Bainbridge et al., 2008; Maguire et al., 2008). rAAV encoding appropriate transgenes may also be of use in the treatment of progressive neurodegenerative diseases such as…”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“…gene replacement therapy has resulted in a gain of visual function in patients with the inherited blinding disease Leber’s congenital amaurosis (Bainbridge et al., 2008; Maguire et al., 2008). rAAV encoding appropriate transgenes may also be of use in the treatment of progressive…”
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“Depending upon vector type and target tissue, this process can take many days until therapeutic protein levels are suf-ficient (Blits et al., 2010; Mason et al., 2010; McCarty et al., 2001; Rabinowitz et al., 2002; Zincarelli et al., 2008).”
Nadal-Nicola´s, F. M., Jime´nez-Lo´pez, M., Sobrado-Calvo, P., Nieto-Lo´pez, L., Ca´novas-Marti´nez, I., Salinas-Navarro, M., Vidal-Sanz, M., & Agudo, M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3267 · Cited by 541 · cited 2×
“…axotomy and is already well advanced 1 week after neurotrauma (Berkelaar et al., 1994; Garcia-Valenzuela et al., 1994; Mansour-Robaey et al., 1994; Nadal-Nicola´s et al., 2009), which is during the period of onset of CNTF transgene expression when the rAAV2 vector is injected at the time of…”
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
Hellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142 · cited 3×
“, 2006), or on pseudo-serotyped vectors (Hellström et al., 2009; Sweigard et al., 2010; Von Seggern et al., 2003), or vectors that carry the self-complimentary RNA strand (Kong et al.”
InfluentialSelf-citationNatkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138 · cited 1×
“…Thomas et al., 2000; Yanez-Munoz et al., 2006), or on pseudo-serotyped vectors (Hell-stro¨m et al., 2009; Sweigard et al., 2010; Von Seggern et al., 2003), or vectors that carry the self-complimentary RNA strand (Kong et al., 2010; Natkunarajah et al., 2008; Wang et al., 2003; Yokoi et al., 2007).”
Rahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Ocular gene transfer with self-complementary AAV vectors
Yokoi, K., Kachi, S., Zhang, H. S., Gregory, P. D., Spratt, S. K., Samulski, R. J., & Campochiaro, P. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1306 · Cited by 58
Cited by
The molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Wong, K. A., & Benowitz, L. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710179 · Cited by 66
Boyd, R. F., Boye, S. L., Conlon, T. J., Erger, K. E., Sledge, D. G., Langohr, I. M., Hauswirth, W. W., Komáromy, A. M., Boye, S. E., Petersen-Jones, S. M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.31 · Cited by 37
Wang, D., Luo, M., Huang, B., Gao, W., Jiang, Y., Li, Q., Nan, K., & Lin, S. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748759 · Cited by 38
“Thus, we presumed that localized co-delivery of FK506 and CNTF in situ may suppress microglia over activation, restore the neurotrophins supply and can effectively protect RGCs post TON.”
BackgroundInfluential
Metadata
- Authors
- Hellström, M., Pollett, M. A., & Harvey, A. R.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2011-12
- Volume
- 28
- Issue
- 12
- Pages
- 2475-2483
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W1986964725
- Cited by
- 55
- References
- 11
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.